作者: R.L. Mani , M.F.W. Smith
DOI: 10.1159/000224441
关键词:
摘要: Targeting the epidermal growth factor receptor (EGFR) has proven to be of clinical benefit in management metastatic colorectal cancer (mCRC). While use small-molecule tyrosine kinase inhibitors this setting not shown any significant activity and been associated with increased gastrointestinal toxicity when combined chemotherapy, a different picture emerged EGFR-targeting monoclonal antibodies.